Donate

industry_news_banner

Bioverativ announced on June 12, 2017 that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for BIVV001 (also known as rFVIIIFc-VWF-XTEN), a novel, investigational factor VIII therapy designed to potentially extend protection from bleeds with prophylaxis dosing of once weekly or longer for people with hemophilia A. Read the press release in full from Bioverativ here.

Facebook Comments


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.